X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop a CLDN18.2 companion diagnostic to support phase III of TST001 (osemitamab) in combination with nivolumab and chemotherapy in patients with CLDN18.2 expressing locally advanced or metastatic gastroesophageal adenocarcinoma.
Lead Product(s): Osemitamab,Nivolumab
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Agilent Technology Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 08, 2024
Details:
TST001 (osemitamab) is a high affinity humanized anti-Claudin18.2 mAb with enhanced ADCC and CDC activities and potent anti-tumor activities in tumor xenograft models. It is being investigated in combination with CAPOX for gastric/gastro-esophageal junction cancer.
Lead Product(s): Osemitamab,Nivolumab
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
TST002 (blosozumab) is a humanized anti-sclerostin mAb for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, enhancing bone mineral density.
Lead Product(s): Blosozumab
Therapeutic Area: Musculoskeletal Product Name: TST002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2023
Details:
TST001 (osemitamab) is a high affinity humanized anti-Claudin18.2 mAb with enhanced ADCC and CDC activities and potent anti-tumor activities in tumor xenograft models. It is being investigated in combination with CAPOX for gastric/gastro-esophageal junction cancer.
Lead Product(s): Osemitamab,Nivolumab
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2023
Details:
TST002 (blosozumab) is a humanized anti-sclerostin mAb for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, enhancing bone mineral density.
Lead Product(s): Blosozumab
Therapeutic Area: Musculoskeletal Product Name: TST002
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
TST001 (osemitamab) is a high affinity humanized anti-Claudin18.2 mAb with enhanced ADCC and CDC activities and potent anti-tumor activities in tumor xenograft models. It is being investigated in combination with CAPOX for gastric/gastro-esophageal junction cancer.
Lead Product(s): Osemitamab,Oxaliplatin,Capecitabine
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2023
Details:
TST001 (osemitamab) is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("ADCC") and complement-dependent cytotoxicity ("CDC") activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Nivolumab
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2023
Details:
TST010 is an anti-CD25 mAb which displayed potent and selective Treg depleting activity and can liberate T effectors in tumor microenvironment to induce immune mediated killing of cancer cells in preclinical tumor models.
Lead Product(s): TST010
Therapeutic Area: Oncology Product Name: TST010
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
TST003 is a high affinity monoclonal antibody targeting Gremlin1, a member of TGFb superfamily. Gremlin1 is highly upregulated in multiple solid tumors.
Lead Product(s): TST003
Therapeutic Area: Oncology Product Name: TST003
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
TST001 (Osemitamab) is a high affinity humanized anti-Claudin18.2 monoclonal antibody with enhanced antibody-dependent cellular cytotoxicity ("ADCC") and complement-dependent cytotoxicity ("CDC") activities and potent anti-tumor activities in tumor xenograft models.
Lead Product(s): TST001,Nivolumab
Therapeutic Area: Oncology Product Name: TST001
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
